Home
GILD
GILD News

Latest Gilead Sciences Inc. (GILD) News on March 30, 2025

Gilead Sciences (NasdaqGS:GILD) Faces Shareholder Proposals As Stock Rises 5%

Simply Wall St.

2 days ago

Gilead Sciences (NasdaqGS:GILD) Faces Shareholder Proposals As Stock Rises 5%

High Growth Tech Stocks in the US Market

Simply Wall St.

3 days ago

High Growth Tech Stocks in the US Market

MT Newswires

3 days ago

JPMorgan Adjusts Price Target on Gilead Sciences to $130 From $120, Maintains Overweight Rating

Gilead’s HIV Treatments Could Face Headwinds. Why the Stock Will Still Rise.

Barrons.com

4 days ago

Gilead’s HIV Treatments Could Face Headwinds. Why the Stock Will Still Rise.

Are Medical Stocks Lagging Gilead Sciences (GILD) This Year?

Zacks

4 days ago

Are Medical Stocks Lagging Gilead Sciences (GILD) This Year?

Gilead Sciences: Using Lessons From the HIV Epidemic To Help Reduce Stigma Around Lung Cancer

ACCESS Newswire

5 days ago

Gilead Sciences: Using Lessons From the HIV Epidemic To Help Reduce Stigma Around Lung Cancer

Gilead Sciences (GILD) Stock Drops Despite Market Gains: Important Facts to Note

Zacks

6 days ago

Gilead Sciences (GILD) Stock Drops Despite Market Gains: Important Facts to Note

Trump Trade: President to sign EO on DOE, weighing Chevron license extension

TipRanks

9 days ago

Trump Trade: President to sign EO on DOE, weighing Chevron license extension

Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN)

StockStory

9 days ago

Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN)

The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics

Zacks

9 days ago

The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics

Gilead Sciences (GILD) Suffers a Larger Drop Than the General Market: Key Insights

Zacks

10 days ago

Gilead Sciences (GILD) Suffers a Larger Drop Than the General Market: Key Insights

GILD Stock Down on Report of Cut in HIV Prevention Spending

Zacks

10 days ago

GILD Stock Down on Report of Cut in HIV Prevention Spending

Oppenheimer doesn’t see threat to Gilead estimates after HHS plans for HIV cuts

TipRanks

10 days ago

Oppenheimer doesn’t see threat to Gilead estimates after HHS plans for HIV cuts

Trump Trade: Reciprocal tariffs still to start on April 2

TipRanks

10 days ago

Trump Trade: Reciprocal tariffs still to start on April 2

Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a Bet

Zacks

10 days ago

Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a Bet

Trump Administration Weighs Deep Cuts To Domestic HIV Prevention Programs, Gilead Stock Slides

Benzinga

10 days ago

Trump Administration Weighs Deep Cuts To Domestic HIV Prevention Programs, Gilead Stock Slides

These Stocks Are Moving the Most Today: Nvidia, Tesla, Autodesk, General Mills, Signet, HealthEquity, and More

Barrons.com

11 days ago

These Stocks Are Moving the Most Today: Nvidia, Tesla, Autodesk, General Mills, Signet, HealthEquity, and More

A Look Back at Therapeutics Stocks’ Q4 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs The Rest Of The Pack

StockStory

11 days ago

A Look Back at Therapeutics Stocks’ Q4 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs The Rest Of The Pack

Gilead Sciences (GILD): Among the Best Biotech Stocks to Buy According to Billionaires

Insider Monkey

12 days ago

Gilead Sciences (GILD): Among the Best Biotech Stocks to Buy According to Billionaires

GILD Stock Trading Close to Its 52-Week High: Should You Buy or Sell?

Zacks

13 days ago

GILD Stock Trading Close to Its 52-Week High: Should You Buy or Sell?

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Zacks

13 days ago

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Is Gilead Sciences, Inc. (GILD) The Most Undervalued NASDAQ Stock To Buy According To Hedge Funds?

Insider Monkey

13 days ago

Is Gilead Sciences, Inc. (GILD) The Most Undervalued NASDAQ Stock To Buy According To Hedge Funds?

Why Is Biogen (BIIB) Up 1.1% Since Last Earnings Report?

Zacks

16 days ago

Why Is Biogen (BIIB) Up 1.1% Since Last Earnings Report?

Argus Research

16 days ago

Technical Assessment: Neutral in the Intermediate-Term

Why Gilead Sciences, Inc. (GILD) is the Best Pharma Stock to Buy According to Hedge Funds

Insider Monkey

17 days ago

Why Gilead Sciences, Inc. (GILD) is the Best Pharma Stock to Buy According to Hedge Funds

GILD vs. VRTX: Which Stock Is the Better Value Option?

Zacks

17 days ago

GILD vs. VRTX: Which Stock Is the Better Value Option?

Gilead (GILD) Up 10.3% Since Last Earnings Report: Can It Continue?

Zacks

17 days ago

Gilead (GILD) Up 10.3% Since Last Earnings Report: Can It Continue?

Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It

Zacks

17 days ago

Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It

Biotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & More

Zacks

17 days ago

Biotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & More

GILD Data on Once-Yearly Lenacapavir for HIV Prevention Positive

Zacks

18 days ago

GILD Data on Once-Yearly Lenacapavir for HIV Prevention Positive

Analyst Says Gilead Sciences (GILD) is a ‘Big Liquid’ Stock You Should Pay Attention To

Insider Monkey

18 days ago

Analyst Says Gilead Sciences (GILD) is a ‘Big Liquid’ Stock You Should Pay Attention To

Gilead Sciences (NasdaqGS:GILD) Advances HIV Treatment With Promising Lenacapavir And Biktarvy Data

Simply Wall St.

18 days ago

Gilead Sciences (NasdaqGS:GILD) Advances HIV Treatment With Promising Lenacapavir And Biktarvy Data

Gilead Presents New HIV Treatment And Cure Research Data

Benzinga

18 days ago

Gilead Presents New HIV Treatment And Cure Research Data

The Zacks Analyst Blog Highlights Exelon, Gilead Sciences, Plains All American Pipeline, Sportradar and Cintas

Zacks

18 days ago

The Zacks Analyst Blog Highlights Exelon, Gilead Sciences, Plains All American Pipeline, Sportradar and Cintas

Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option

Business Wire

18 days ago

Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option

Gilead to launch Phase III once-yearly HIV PrEP trial after Phase I success

Clinical Trials Arena

18 days ago

Gilead to launch Phase III once-yearly HIV PrEP trial after Phase I success

A new obesity biotech launches; Gilead plans to quickly advance once-yearly PrEP for HIV

BioPharma Dive

18 days ago

A new obesity biotech launches; Gilead plans to quickly advance once-yearly PrEP for HIV

These 3 Attractive Stocks Keep Cruising Higher

Zacks

19 days ago

These 3 Attractive Stocks Keep Cruising Higher

MT Newswires

19 days ago

Gilead Sciences Once-yearly HIV Prevention Treatment Safe, Well Tolerated in Study

First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet

Business Wire

19 days ago

First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet

Buy 5 Non-Tech High-Flying Nasdaq Stocks Amid Index's Recent Bloodbath

Zacks

19 days ago

Buy 5 Non-Tech High-Flying Nasdaq Stocks Amid Index's Recent Bloodbath

MT Newswires

19 days ago

Morgan Stanley Adjusts Price Target on Gilead Sciences to $130 From $123, Keeps Overweight Rating

Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks

StockStory

19 days ago

Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks

The Top Nasdaq-100 Stock in 2025 Has Nothing to Do With Artificial Intelligence (AI)

Motley Fool

19 days ago

The Top Nasdaq-100 Stock in 2025 Has Nothing to Do With Artificial Intelligence (AI)

Zacks Investment Ideas feature highlights: Gilead Sciences and Johnson & Johnson

Zacks

20 days ago

Zacks Investment Ideas feature highlights: Gilead Sciences and Johnson & Johnson

Is Gilead Sciences (GILD) Stock Outpacing Its Medical Peers This Year?

Zacks

20 days ago

Is Gilead Sciences (GILD) Stock Outpacing Its Medical Peers This Year?

1 Value Stock with Exciting Potential and 2 to Ignore

StockStory

20 days ago

1 Value Stock with Exciting Potential and 2 to Ignore

CDC plans study into potential vaccines, autism connections, Reuters reports

TipRanks

22 days ago

CDC plans study into potential vaccines, autism connections, Reuters reports

Buy Gilead Sciences (GILD) Stock at 52-Week Highs?

Zacks

22 days ago

Buy Gilead Sciences (GILD) Stock at 52-Week Highs?

Gilead Sciences' (NASDAQ:GILD) Conservative Accounting Might Explain Soft Earnings

Simply Wall St.

23 days ago

Gilead Sciences' (NASDAQ:GILD) Conservative Accounting Might Explain Soft Earnings

3 Healthcare Stocks With Strong EPS Growth Potential to Buy in 2025

Zacks

23 days ago

3 Healthcare Stocks With Strong EPS Growth Potential to Buy in 2025

Johnson & Johnson and 4 Other Biopharmaceutical Stocks That Might Be Ready to Break Out

Barrons.com

25 days ago

Johnson & Johnson and 4 Other Biopharmaceutical Stocks That Might Be Ready to Break Out

MT Newswires

25 days ago

BofA Securities Adjusts Gilead Sciences Price Target to $126 From $116, Maintains Buy Rating

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

Zacks

25 days ago

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

Gilead Sciences, Inc. (GILD) Hits Fresh High: Is There Still Room to Run?

Zacks

25 days ago

Gilead Sciences, Inc. (GILD) Hits Fresh High: Is There Still Room to Run?

MT Newswires

25 days ago

Wells Fargo Adjusts Price Target on Gilead Sciences to $140 From $120, Keeps Overweight Rating

Pharmaceutical Stocks Hit New Highs Amid Market Volatility

Zacks

a month ago

Pharmaceutical Stocks Hit New Highs Amid Market Volatility

Discover Gilead Sciences And 2 More Stocks That May Be Priced Below Intrinsic Estimates

Simply Wall St.

a month ago

Discover Gilead Sciences And 2 More Stocks That May Be Priced Below Intrinsic Estimates

MT Newswires

a month ago

Oppenheimer Adjusts Price Target on Gilead Sciences to $132 From $115, Keeps Outperform Rating

Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts

Zacks

a month ago

Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts

Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.79

Simply Wall St.

a month ago

Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.79

MT Newswires

a month ago

Jefferies & Co. Adjusts Gilead Sciences Price Target to $130 From $115, Maintains Buy Rating

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Zacks

a month ago

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Wall Street Bulls Look Optimistic About Gilead (GILD): Should You Buy?

Zacks

a month ago

Wall Street Bulls Look Optimistic About Gilead (GILD): Should You Buy?

Drug Stocks Are the New Safe Bet in a Shaky Market

The Wall Street Journal

a month ago

Drug Stocks Are the New Safe Bet in a Shaky Market

Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know

Zacks

a month ago

Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know

Patient Insight Institute announces partnership to improve cancer screening

Hospital Management

a month ago

Patient Insight Institute announces partnership to improve cancer screening

Biotech Stock Roundup: BLUE Down on Update, News From GILD, TRDA

Zacks

a month ago

Biotech Stock Roundup: BLUE Down on Update, News From GILD, TRDA

The Zacks Analyst Blog Highlights Charles Schwab, Gilead, Medtronic, Cooper-Standard and Rave Restaurant

Zacks

a month ago

The Zacks Analyst Blog Highlights Charles Schwab, Gilead, Medtronic, Cooper-Standard and Rave Restaurant

Zacks.com featured highlights Gilead Sciences, Exelixis, Synchrony Financial and Molson Coors

Zacks

a month ago

Zacks.com featured highlights Gilead Sciences, Exelixis, Synchrony Financial and Molson Coors

Top Stock Reports for Charles Schwab, Gilead Sciences & Medtronic

Zacks

a month ago

Top Stock Reports for Charles Schwab, Gilead Sciences & Medtronic

Investing.com

a month ago

Morgan Stanley sees FDA approval of GILD's Lenacapavir

Argus Research

a month ago

The Argus High-Yield Model Portfolio

4 PEG-Based GARP Picks to Weather 2025 Market Uncertainty

Zacks

a month ago

4 PEG-Based GARP Picks to Weather 2025 Market Uncertainty

Gilead’s lenacapavir applications for HIV gain EMA validation

Pharmaceutical Technology

a month ago

Gilead’s lenacapavir applications for HIV gain EMA validation

MT Newswires

a month ago

Gilead Sciences Says Potential HIV Prophylaxis Applications Under Parallel Accelerated Review in EU

European Medicines Agency Validates Gilead’s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention

Business Wire

a month ago

European Medicines Agency Validates Gilead’s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention

Argus Research

a month ago

Technical Assessment: Bullish in the Intermediate-Term

Gilead Sciences, Inc. (GILD): Among Renaissance Technologies Portfolio’s Top Stock Picks

Insider Monkey

a month ago

Gilead Sciences, Inc. (GILD): Among Renaissance Technologies Portfolio’s Top Stock Picks

Argus Research

a month ago

Analyst Report: Gilead Sciences, Inc.

Gilead’s lenacapavir under priority review could revolutionise HIV PrEP

Clinical Trials Arena

a month ago

Gilead’s lenacapavir under priority review could revolutionise HIV PrEP

Argus Research

a month ago

Market Update: BKNG, THRM, DHI, GILD, WMT, XYZ

MT Newswires

a month ago

Bernstein Adjusts Gilead Sciences Price Target to $120 From $105

Some Investors May Be Willing To Look Past Gilead Sciences' (NASDAQ:GILD) Soft Earnings

Simply Wall St.

a month ago

Some Investors May Be Willing To Look Past Gilead Sciences' (NASDAQ:GILD) Soft Earnings

Gilead's new HIV med, a bird flu shot for chickens, and Hims does blood tests: Pharma news roundup

Quartz

a month ago

Gilead's new HIV med, a bird flu shot for chickens, and Hims does blood tests: Pharma news roundup

MT Newswires

a month ago

Gilead Sciences Gets Conditional Marketing Authorization for Liver Disease Treatment in European Economic Area

Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis

Business Wire

a month ago

Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis

GILD or VRTX: Which Is the Better Value Stock Right Now?

Zacks

a month ago

GILD or VRTX: Which Is the Better Value Stock Right Now?

Gilead Sciences, Inc. (GILD): Among Stocks That Analysts Think Will Go Up

Insider Monkey

a month ago

Gilead Sciences, Inc. (GILD): Among Stocks That Analysts Think Will Go Up

Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year?

Zacks

a month ago

Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year?

High Growth Tech Stocks in the United States to Watch

Simply Wall St.

a month ago

High Growth Tech Stocks in the United States to Watch

Gilead Sciences to Present at Upcoming Investor Conferences

Business Wire

a month ago

Gilead Sciences to Present at Upcoming Investor Conferences

Biotech Stock Roundup: MRNA's Q4 Results, GILD's Update & Other News

Zacks

a month ago

Biotech Stock Roundup: MRNA's Q4 Results, GILD's Update & Other News

Sanofi reaches consumer health deal; Supernus antidepressant fails study

BioPharma Dive

a month ago

Sanofi reaches consumer health deal; Supernus antidepressant fails study

Gilead’s lenacapavir moves closer to FDA approval for HIV PrEP use

Pharmaceutical Technology

a month ago

Gilead’s lenacapavir moves closer to FDA approval for HIV PrEP use

Gilead Sciences Full Year 2024 Earnings: Beats Expectations

Simply Wall St.

a month ago

Gilead Sciences Full Year 2024 Earnings: Beats Expectations

A new HIV prevention drug could get FDA approval this year

Quartz

a month ago

A new HIV prevention drug could get FDA approval this year

Investing.com

a month ago

Deutsche Bank upgrades Gilead on its HIV treatment franchise

MT Newswires

a month ago

Cantor Fitzgerald Adjusts Gilead Sciences Price Target to $100 From $80, Maintains Neutral Rating

MT Newswires

a month ago

DBS Bank Adjusts Gilead Sciences Price Target to $125 From $100

Share on Social Networks: